Promising therapeutics. Patient-centric value.
Our drug development approach is aimed at identifying, licensing, and acquiring novel clinical-stage assets that target unmet patient needs
At Nexstone Immunology, we are focused on transforming the treatment of a broad array of immune-mediated diseases through the development and delivery of promising therapeutics that are tailored to the needs of underserved patient populations.
We are dedicated to bringing new patient value to the treatment of immune-mediated diseases.
As a Blackstone Life Sciences portfolio company, Nexstone Immunology is operationally agile and clinically adept with the ability to deliver new value to underserved patient populations. In addition to advancing our lead Phase 2-ready human monoclonal antibody, we are fueling future growth by actively evaluating the licensing and acquisition of promising drug candidates that are synergistic with our drug development approach and target unmet patient needs.